53 related articles for article (PubMed ID: 8387803)
1. Chondroitin sulfate iron colloid as MR contrast agent in differentiation between hepatocellular carcinoma and adenomatous hyperplasia.
Suto Y; Kato T; Matsuo T; Kamba M; Shimatani Y; Ohuchi Y; Nakamura K; Ohta Y
Acta Radiol; 1993 May; 34(3):226-9. PubMed ID: 8387803
[TBL] [Abstract][Full Text] [Related]
2. Correlation between chondroitin sulfate iron colloid-enhanced MR imaging and the histological grade of hepatocellular carcinoma.
Suto Y; Kodama F; Kamba M; Ohta Y
Acta Radiol; 1995 Jan; 36(1):102-5. PubMed ID: 7833161
[TBL] [Abstract][Full Text] [Related]
3. A study of chondroitin sulfate iron colloid as a liver specific MR contrast agent.
Hussain MZ; Ohtomo K; Kachi K; Uchiyama G; Itai Y
Radiat Med; 1994; 12(1):1-5. PubMed ID: 8016397
[TBL] [Abstract][Full Text] [Related]
4. Chondroitin sulfate iron colloid-enhanced MR imaging in patients with hepatocellular carcinoma. Comparison with CT during arterial portography.
Kamba M; Suto Y; Kato T
Acta Radiol; 1994 Nov; 35(6):570-5. PubMed ID: 7946680
[TBL] [Abstract][Full Text] [Related]
5. Double contrast MR imaging with iron colloid and Gd-DTPA in cholangiocellular carcinoma.
Suto Y; Shimatani Y; Kato T; Kamba M; Ohuchi Y; Kodama F; Kato T; Ohta Y
Acta Radiol; 1994 Nov; 35(6):632-3. PubMed ID: 7946691
[TBL] [Abstract][Full Text] [Related]
6. Time-course changes of contrast enhancement in iron colloid enhanced MRI in patients with hepatocellular carcinoma.
Suto Y; Ametani M; Kamba M; Sugihara S
Br J Radiol; 1996 Mar; 69(819):201-5. PubMed ID: 8800862
[TBL] [Abstract][Full Text] [Related]
7. Conspicuity of liver hemangiomas: short tau inversion recovery, T1, and T2 imaging with gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid.
Brody JM; Schafer L; Tung GA; Breuer J; Shamsi K
J Magn Reson Imaging; 2005 Apr; 21(4):391-7. PubMed ID: 15778951
[TBL] [Abstract][Full Text] [Related]
8. Optimum conditions for iron colloid enhanced fast spin echo imaging in hepatocellular carcinoma.
Sugihara S; Suto Y; Yoshida K
Br J Radiol; 1997 Aug; 70(836):791-7. PubMed ID: 9486042
[TBL] [Abstract][Full Text] [Related]
9. [Superparamagnetic iron oxide-enhanced magnetic resonance imaging of hepatocellular carcinoma in rats].
Liu X; Xu YK; Huang QL; Wu YK
Di Yi Jun Yi Da Xue Xue Bao; 2002 Dec; 22(12):1061-5. PubMed ID: 12480574
[TBL] [Abstract][Full Text] [Related]
10. Dual contrast magnetic resonance imaging with combined use of positive and negative contrast agent in human hepatocellular carcinoma.
Suto Y; Shimatani Y
Br J Radiol; 1995 Feb; 68(806):116-20. PubMed ID: 7735739
[TBL] [Abstract][Full Text] [Related]
11. Mangafodipir trisodium-enhanced MRI for the detection and characterization of focal hepatic lesions: is delayed imaging useful?
Chung JJ; Kim MJ; Kim KW
J Magn Reson Imaging; 2006 May; 23(5):706-11. PubMed ID: 16565954
[TBL] [Abstract][Full Text] [Related]
12. [Hepatic and hepatocarcinoma magnetic resonance: comparison of the results obtained with paramagnetic (gadolinium) and superparamagnetic (iron oxide particles) contrast media].
Castoldi MC; Fauda V; Scaramuzza D; Vergnaghi D
Radiol Med; 2000 Sep; 100(3):160-7. PubMed ID: 11148882
[TBL] [Abstract][Full Text] [Related]
13. MR imaging of hepatocellular carcinoma.
Onaya H; Itai Y
Magn Reson Imaging Clin N Am; 2000 Nov; 8(4):757-68. PubMed ID: 11149678
[TBL] [Abstract][Full Text] [Related]
14. Adenomatous hyperplastic nodules in the cirrhotic liver: differentiation from hepatocellular carcinoma with MR imaging.
Matsui O; Kadoya M; Kameyama T; Yoshikawa J; Arai K; Gabata T; Takashima T; Nakanuma Y; Terada T; Ida M
Radiology; 1989 Oct; 173(1):123-6. PubMed ID: 2550995
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of [Gd(Bz-TTDA)]2- as a potential contrast agent in MR imaging of the hepatobiliary system: an animal study.
Hsu JS; Jaw TS; Liu GC; Wang YM; Chen SH; Kuo YT; Jao JC; Li CW; Tsai KB
J Magn Reson Imaging; 2004 Oct; 20(4):632-9. PubMed ID: 15390149
[TBL] [Abstract][Full Text] [Related]
16. Hepatocellular carcinoma exhibiting a concentric structure of different histologic grades: evaluation by chondroitin sulfate iron colloid-enhanced MR imaging.
Kamba M; Suto Y; Kodama F; Ohta Y; Kobayashi J; Horie Y; Kawasaki H
J Magn Reson Imaging; 1996; 6(2):406-8. PubMed ID: 8859586
[TBL] [Abstract][Full Text] [Related]
17. Usefulness of iron colloid-enhanced MRI in differentiating experimental hepatocellular carcinoma from hyperplastic nodules in rats: analysis by microautoradiography.
Suto Y; Kodama F
Br J Radiol; 1996 Dec; 69(828):1139-44. PubMed ID: 9135470
[TBL] [Abstract][Full Text] [Related]
18. [A preliminary study on MR lymphography with iron chondroitin sulfate colloid].
Okuhata Y; Urahashi S; Kamata R; Arimizu N
Nihon Igaku Hoshasen Gakkai Zasshi; 1990 Jun; 50(6):671-3. PubMed ID: 2122415
[TBL] [Abstract][Full Text] [Related]
19. Chondroitin sulfate iron colloid as an MR contrast agent for the hepatic reticuloendothelial system.
Kato T; Suto Y; Matsuo T
J Comput Assist Tomogr; 1993; 17(4):603-8. PubMed ID: 8392526
[TBL] [Abstract][Full Text] [Related]
20. Small hepatocellular carcinoma: relationship of signal intensity to histopathologic findings and metal content of the tumor and surrounding hepatic parenchyma.
Ebara M; Fukuda H; Kojima Y; Morimoto N; Yoshikawa M; Sugiura N; Satoh T; Kondo F; Yukawa M; Matsumoto T; Saisho H
Radiology; 1999 Jan; 210(1):81-8. PubMed ID: 9885591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
